Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
September 1, 2024
Imatinib cessation after a good response in met-GIST should not be considered. Based on this study’s results patients should be left on therapy until disease progression or toxicity issues.
